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Abstract
Background: Chronic kidney disease (CKD) is a substantial cause of morbidity and mortality worldwide with
disproportionate effects in sub-Saharan Africa (SSA). The optimal methods to estimate glomerular filtration rate
(GFR) and therefore to determine the presence of CKD in SSA are uncertain. We plan to measure iohexol excretion
to accurately determine GFR in Malawi, South Africa and Uganda. We will then assess the performance of existing
equations to estimate GFR and determine whether a modified equation can better improve estimation of GFR in
sub-Saharan Africa.
Methods: The African Research on Kidney Disease (ARK) study is a three-country study embedded within existing
cohorts. We seek to enrol 3000 adults > 18 years based on baseline serum creatinine. Study procedures include
questionnaires on socio-demographics and established risk factors for kidney disease along with anthropometry,
body composition, blood pressure, blood chemistry and urine microscopy and albuminuria. We will measure GFR
(mGFR) by plasma clearance of iohexol at 120, 180 and 240 min. We will compare eGFR determined by established
equations with mGFR using Bland-Altman plots. We will use regression methods to estimate GFR and compare the
newly derived model with existing equations.
Discussion: Through the ARK study, we aim to establish the optimal approach to estimate GFR in SSA. The study
has the advantage of drawing participants from three countries, which will increase the applicability of the findings
across the region. It is also embedded within established cohorts that have longitudinal information and serial
measures that can be used to characterize kidney disease over a period of time. This will help to overcome the
limitations of previous research, including small numbers, selected population sub-groups, and lack of data on
proteinuria.
The ARK collaboration provides an opportunity for close working partnerships across different centres, using
standardized protocols and measurements, and shared bio-repositories. We plan to build on the collaboration for
this study for future work on kidney disease in sub-Saharan Africa, and welcome additional partners from across the
continent.
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Background
Chronic kidney disease (CKD) is a substantial cause of
morbidity and mortality worldwide with an estimated
prevalence of 8–16% [1]. A recent systematic review esti-
mated the prevalence of CKD in sub-Saharan Africa to
be around 14% [2]. However, the optimal equation to ac-
curately estimate glomerular filtration rate (GFR) among
sub-Saharan African populations is uncertain. This un-
certainty is a major barrier to identifying individuals
with CKD and to estimation of disease burden.
Worldwide, several equations have been used to esti-
mate GFR from serum creatinine [3–7]. Unfortunately,
most of these have been derived from high-income
countries with minimal validation in sub-Saharan Afri-
can populations. Their accuracy at an individual level is
limited, particularly in relation to the adjustments for
African-American ethnicity, which might be related to
variations in muscle mass. Serum creatinine levels at a
given level of renal function vary substantially with eth-
nicity, age, sex, physical activity and nutritional status
[8–14]. Several sources of inaccuracy in estimating GFR
have been described, including biological variability in
serum creatinine, laboratory induced errors in creatinine
measurement and choice of estimating equation [15, 16].
The imprecision of creatinine measurement is more
marked at values near the normal range where it is most
critical to determine earlier stages of CKD [17–19]. Sev-
eral methods for direct measurement of GFR are avail-
able through measurement of clearance of inulin,
iothalamate, iohexol, and radio-active agents such as
technetium-99 m diethylenetriamine penta-acetic acid
(DTPA) and chromium-51 ethylene diamine tetra-acetic
acid (EDTA), and 24-h urinary creatinine collection for
estimation of creatinine clearance [20]. However, all of
these have their challenges. DTPA, EDTA and inulin are
expensive and not readily available in most African
countries, while 24-h urinary collection is often inaccur-
ate due to difficulty in ensuring a complete sample,
coupled with the additional limitation of tubular creatin-
ine secretion [20–22].
Iohexol is a readily available compound, which can be
used to measure the GFR. Its advantages include low
cost, excellent safety profile, low protein binding, low
levels of toxicity at the dose used for measuring GFR,
stability at room temperature (20 to 25 °C), and being
able to provide an accurate measure of glomerular filtra-
tion [20, 23]. Previous studies using iohexol to measure
GFR in sub-Saharan Africa have included few people
with CKD [13, 24, 25]. The largest study to date con-
ducted in the Democratic Republic of Congo and Ivory
Coast used plasma iohexol to measure GFR in 494 par-
ticipants. They noted that the African-American race co-
efficient did not improve the performance of creatinine-
based GFR estimates of iohexol GFR. In particular, the
Chronic Kidney Disease Epidemiology (CKD-EPI) and
Modification of Diet in Renal Disease (MDRD) equa-
tions performed better without the race coefficient in
participants with GFR ≥60mL/min/1.73m2. The authors
also evaluated the Full Age Spectrum (FAS) equation
and found it to be as accurate as CKD-EPI for GFR ≥60
mL/min/1.73m2 but better for those with creatinine
based GFR < 60mL/min/1.73m2. Addition of cystatin C
did not improve performance of the equations among
this study group [25].
In the proposed study, we will use iohexol excretion in
a population sample of 3000 participants with and with-
out CKD to measure GFR and determine the optimal
equation to estimate GFR in Uganda, Malawi and South
Africa.
Methods
Primary objectives
1. To measure GFR using plasma clearance of iohexol
2. To assess the performance of existing eGFR
equations, namely Cockcroft -Gault (CG),
Modification of Diet in Renal Disease (4-v MDRD)
and Chronic Kidney Disease-Epidemiology
collaboration (CKD-EPI) by comparing these to
measured GFR, among sub-Saharan Africans.
Secondary objectives
In a Ugandan sub-sample, to assess the feasibility of
using dry blood spot collection of iohexol in the deter-
mination of GFR.
In a Ugandan sub-sample to explore the current com-
munity understanding of kidney disease and available
treatments from traditional healers and herbalists.
Study organization and sites
We will have three participant countries across SSA
(Fig. 1) and these centres have formed a new collabora-
tive group, African Research on Kidney Disease (ARK)
around this initial study.
A working committee will review the protocols for the
design, conduct, progress and data collection and ana-
lysis plan. The committee will meet in person on several
occasions to review protocols and measurement tools
and to agree on a minimum dataset. The three centres
have unique characteristics that will enrich the study
with diversity among participants. The details of each of
the different cohorts in which the current study will be
nested are described below:
Uganda
In Uganda, the study will be based in the General Popu-
lation Cohort (GPC), originally established in 1989 [26].
The study area is located in rural south-western Uganda
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in one sub-county of Kalungu district, approximately
120 km from Entebbe town. The cohort comprises all
residents of 25 adjacent villages, approximately 22,000
people with men and women in equal proportions, and
52% older than 13 years. The study population for the
general population cohort is recruited through annual
house-to-house rounds of the census where study partic-
ipants are selected. Medical care is available through an
established general clinic.
Malawi
The Malawi Epidemiology and Intervention Research Unit
(MEIRU) conducts ongoing epidemiological studies based
at two sites, which will be used for recruiting participants
for this study. The first is Karonga District in rural north-
ern Malawi, predominantly subsistence farmers, fishermen
and informal traders. The second site is Area 25 of
Lilongwe, the capital city of Malawi. The urban area is
socio-economically mixed and includes government and
industry employees, traders and those in casual employ-
ment. We will enrol participants from both sites, provid-
ing a true population-wide sample and enabling urban:
rural comparisons.
The stratified study sample was drawn from a pool of
over 5000 individuals who were tested for serum creatin-
ine as part of a larger survey (n = 33,000) of chronic con-
ditions. Medical care is available through an established
chronic care Non-Communicable Disease (NCD) clinic.
South Africa
In South Africa, the study will be located within the Med-
ical Research Council/University of the Witwatersrand
Fig. 1 Map of Africa showing the ARK centres from Malawi, South Africa and Uganda. The general population cohort is run by the Medical
Research Council-Uganda virus Institute and the London School of Hygiene and tropical Medicine (MRC-UVRI-LSHTM, Uganda). The Malawi
Epidemiology and Intervention Research Unit (MEIRU) runs the MEIRU cohort in Malawi and the Medical Research Council/Wits University Rural
Public Health and Health Transitions Research Unit runs the Agincourt Unit in South Africa. Map proposed by Robert Kalyesubula and illustrated
by Helmut Kraus
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Rural Public Health and Health Transitions Research Unit
in Agincourt, Bushbuckridge sub-district of Mpumalanga
province. The area includes a high-functioning health and
socio-demographic surveillance system (HDSS) which
covers approximately 115,000 people based on an annual
update of resident status and vital events. The study set-
ting also serves as a national pilot site for the development
of integrated chronic disease care. The population still has
gaps in access to electricity, water and tarred roads and
unemployment rates are high, leading to high rates of
labour migration. Patients will be managed through the
primary health care system consisting of six clinics, two
health centres and three district hospitals. The HDSS has
a central clinic with advanced laboratory capacity, which
will be used for this study.
Study design
This will consist of cross-sectional studies embedded
within ongoing cohorts in Malawi and Uganda and a
longitudinal study in South Africa, all with serial bio-
banking.
Data collection, sample size and selection of sample
We intend to recruit 3000 participants in total. We have
based the power calculation is based on the number of
study participants needed to examine the accuracy of
GFR estimating equations for ‘true’ GFR, at each of the
three study sites separately. We have specified this as
having 90% power to detect whether eGFR is within 5%
of the iohexol value at an eGFR of 60mls/min, assuming
a standard deviation of 25mls/min [9] and with a two-
sided alpha of 0.05. This gives an estimated required
sample size of 730 participants. Allowing for participants
who do not wish to participate in this element of the
study, and technical failures, we intend to recruit 1000
participants in each country.
In order to fulfil the aims of the study, a structured ap-
proach is needed. This will differ between South Africa
and the other two sites (Malawi and Uganda).
Details of site recruitment
We plan to recruit from each of the sites guided by the
previous recruitment protocols. Each of the sites will
however, have two phases of recruitment.
For the Uganda GPC, the first phase will consist of
measurement of creatinine from stored sera.
Participant selection for this part of the study has been
described elsewhere [27]. Briefly, participants were se-
lected from the general population cohort, which is a
community-based open cohort study of residents of 25
neighbouring villages. The participants are selected
through house-to-house mobilisation and community
surveys conducted through village-based hubs. For
Uganda, 5979 individuals were identified for baseline
creatinine measurement, which included all the adults
surveyed in that round. We will use creatinine levels
from the stored samples to stratify participants for the
second phase of the study. Here, we will select partici-
pants according to eGFR cut offs of normal (>90mls/
min/1.73m2); impaired renal function (60-90mls/min/
1.73m2) and low GFR (<60mls/min/1.73m2), all addition-
ally stratified by age and sex. Selected participants will
be approached by the community engagement lead
(community mobilizer) for each village. Once partici-
pants assemble, the study team will take time to explain
the details of the study to them, after which individual
informed consent will be obtained. Participants will
undertake a questionnaire to collect demographic data
as well as history of known risk factors for kidney dis-
ease. Participants will also undergo detailed biophysical
measurements and blood draws as detailed in the next
sections. We will give participants an appointment to at-
tend the medical clinic at the central Research Station,
where iohexol measurements and other study tests will
be performed.
For Malawi, for the first phase of the study, we will
use creatinine assays from a previous survey to guide the
selection of participants for the second phase of the
study using a similar approach to that of Uganda. How-
ever, we will recruit participants 18 years and above from
Malawi through household visits where similar proce-
dures to those outlined above will be undertaken. We
will carry out iohexol testing and other physical tests at
a research clinic (phase 2). Details of participant recruit-
ment have been detailed elsewhere [28].
In South Africa, we will determine baseline creatinine
and the prevalence of CKD using an age and gender
stratified random sample of 2250 members of the rural
Agincourt HDSS. The number of participants sampled
in each stratum will be determined in order to ensure
proportional allocation, based on the population demo-
graphic distribution. We will visit participants in their
homes for the first phase of the study where the ques-
tionnaires, biophysical measurements and take blood
draws to determine Human immunodeficiency virus
(HIV) status, blood sugar level, lipid profile as well as
the baseline creatinine level. We will repeat creatinine
and urine albumin measures after a minimum period of
3 months to confirm CKD. For the second phase of the
study, we will recruit participants from Phase 1 through
household visits and give them a referral date to the
clinic for iohexol measurement along with other tests
(See Table 1 and Fig. 2 for details).
Inclusion criteria
 Adults aged 18 years and above from the three
population cohorts
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Table 1 Clinical and Laboratory measurements within the ARK study, by country
Type of information Equipment Field procedures Participant type Definition of variable Site participation
Malawi S. Africa Uganda
Demographics Questionnaire Face-to-face interview all Sex, age, education status,
marital status
x x x
Chronic disease history
and family history
Questionnaire /
medical records
Face-to-face interview all HTN, DM, CKD, Stroke, heart
disease
x x x
Treatment history Patient report/
records
Face-to-face interview all HTN, DM, CKD, Stroke,
HIV,TB, Heart disease,
Cancer, Backache
x x x
Health behaviours Patient report Face-to-face interview all Tobacco use, alcohol
consumption, Physical
activity, vegetable, fruits,
salt and water intake
x x
Traditional medicine
use
Questionnaire Face-to-face interview all Use of herbs and
traditional medicines
x x x
Physical examination Omron®
SECA®
Flexible tape
SECA© scales
Clinical Examination
in the field, machines
calibrated weekly
all BP (mmHg), waist and
hip circumferences (cms),
height (m), weight (Kgs)
x x x
ABPM ABPM spacelabs® 24 h BP, 30 min interval
day, 1 h interval night
Sample per
eGFR quarter
BP wake periods and
sleep periods
x x
BIA Bodystat® Tested in the field or
clinic with participant,
calibration weekly
all Fat mass (kg), Lean mass
(kg), Dry lean mass(kg),
Total body water (L),
Impedance at 50 KHZ (Ω)
x x x
DXA SCAN Hologic Discovery A.
QDR 4500 Series
Whole body scan
performed in clinical
research clinic during
iohexol testing
all Lean Mass (g), Fat mass
(g) Fat % and BMI
x
Ultra sound scan Logiq e Performed at clinic all Probe 4c for kidneys and
bladder and probe12L
CIMT probe
x
ECG ECG 300A®/
MAC600®
ECG protocol followed all LVH using the Sokolow-
Lyon criteria
x x x
CBC BC® Venous blood draw all Total cell count, HB,
MCV
x x
24 HR URINE Cobas Roche® urine using small
bucket.
Select patients
for 24 h proteinuria,
salt and feasibility.
Volume (mls) Protein
(mg)
Creatinine (mmol/L)
Na+ mmol/L
x
Malaria screen Malaria RDT® Done in the
community
all Malaria infection x x
CRP Cobas® & BC® Blood draw all CRP x x
Hepatitis B Cobas®
ABBOTT (i1000SR)
Blood draw all HepB SAg x x x
Hepatitis C Cobas® (Uganda),
HCV antibody
rapid test (Malawi)
Blood draw all HepC Ab x x
ASOT Cobas® & BC® Blood draw All > 300 x
HIV screen Alere Dertemine-Stat-
pak-Bio line & Abbott
Determine
MOH serial testing
algorithm
all HIV status x x x
Schistosomiasis Microscopy Examination of
centrifuged urine
all Schistosoma
hematobium
x x x
Microalbuminuria CLINITEK® + analyser
& Cobas® & BC®
ACR all Urine ACR x x x
Urine analysis Clinitek® & UroColor Early morning urine all Protein, blood,
glucose, WBCs,
QuickVue Hcg Urine
for pregnancy
x x x
Lipid profile Cobas® & BC® Blood draw all Cholesterol, LDL, x x
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Table 1 Clinical and Laboratory measurements within the ARK study, by country (Continued)
Type of information Equipment Field procedures Participant type Definition of variable Site participation
Malawi S. Africa Uganda
HDL, TGs
RBS BC® Point of care testing
(Uganda $ SA)
all Diabetes > 11.1 or
on medical treatment
x x x
HBA1C Cobas® & BC® Blood draw All 6.5% or on treatment x x
Creatinine Cobas® & BC® Jaffe and IDMS all For eGFR estimation x x x
Cystatin-C Cobas® all For eGFR estimation x x x
Iohexol Omnipaque
300 mg I/ml
Healthcare®
HPLC®
Clinic based blood
draws at 5, 120, 180
and 240 min after
administration
all Measured GFR x x x
Iohexol, DBS DBS® DBS by finger prick
at 120 and 240 min
300 selected
by eGFR
Validation of measured
GFR technique
x
Aldosterone/Renin Cobas Roche® Selected
population
x x
All biochemistry was tested using Cobas equipment in Uganda and South Africa and Beckman Coulter equipment in Malawi
Abbreviations: ABPM Ambulatory Blood Pressure Monitor, ACR Albumin Creatinine Ratio, ASOT Antistreptococcal antibody titres, BC® Beckman Coulter®, BIA
Bioimpedance Analysis, BP Blood Pressure, CBC Cell blood count, CKD Chronic Kidney Disease, CRP C-Reactive protein, CIMT Carotid intima-medial
thickness, DBS Dry blood sample, DM Diabetes Mellitus, ECG Electrocardiography, eGFR Estimated glomerular filtration rate, HB Haemoglobin, HTN
Hypertension, HPLC High liquid pressure chromatography, IDMS Isotope dilution mass spectrometry, LVH Left ventricular hypertrophy, MCV Mean
corpuscular volume, MOH Ministry of Health, RBS Random blood sugar, SA South Africa, TB Tuberculosis
Fig. 2 Recruitment flowchart for ARK. ABPM- Ambulatory Blood Pressure Monitor; ACR- Albumin: creatinine Ratio; ASOT- Antistreptococcal
antibody titres; BIA- Bioimpedance Analysis; BP-Blood Pressure; CBC- Cell blood count; GFR- glomerular filtration rate; CKD- Chronic kidney disease;
HB-Haemoglobin; NCD-Non-communicable diseases; SA-South Africa. Credit for the ARK study map and copyright go to Helmut Kraus
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 Able to give informed consent
Exclusion criteria
 Blood pressure > 180/110mmhg
 Pregnancy
 Breast-feeding mothers
 Known allergy to iodine−containing substances
 Uncontrolled seizures (defined as a seizure within
the last 12 months).
 Acute febrile illness
Demographic factors
We will collect data on demographic factors including age,
sex, place of residence, education, occupation and liveli-
hood, tobacco use, alcohol use, dietary history, physical ac-
tivity. We will also take a medical history and treatment for
chronic diseases including HIV, diabetes mellitus, hyperten-
sion, heart disease and CKD as well as previous and current
use of traditional medicine and drugs.
Physical examination
We will measure height, weight, waist circumference
and hip circumference and calculate the body mass
index (BMI) and the waist hip ratio accordingly. We will
classify BMI according to WHO categories (weight/
height2: kg/m2): underweight (< 18.5 kg/m2), normal
weight (18.5–24.99 kg/m2), overweight (25.0–29.99 kg/
m2) and obese (> 30.0 kg/m2).
We will undertake cardiovascular assessment through
blood pressure and 24-h ambulatory blood pressure (BP)
measurements (ABPM) on a sub-sample of participants
(Malawi and Uganda), and electrocardiography (ECG).
We will measure BP using Omron® M6 (for small,
medium and large participants) and Omron HBP 110
machines (for obese participants). We will measure BP
in triplicate after at least 5 min of rest and take the mean
of the last two readings as the true blood pressure. We
will derive BP classification from the National Institute
of Health guidelines: where participants with a systolic
BP greater than 120 mmHg but less than 140 mmHg,
and/or a diastolic BP greater than 80 mmHg but less
than 90mmHg will be classified as pre-hypertensive. We
defined hypertension as having a diastolic BP greater
than or equal to 90 mmHg, systolic BP greater than or
equal to 140 mmHg or being on treatment for high
blood pressure. 24-h ambulatory blood pressure will be
undertaken on a selected number of participants with no
hypertension, pre-hypertension and hypertension across
the spectrum of eGFR ranges and will capture wake and
sleep periods. We will use the ECG for assessment of
LVH using the Sokolow-Lyon criteria [29].
We will perform bioimpedance analysis (BIA) using
the Bodystat® machine to measure body fat in relation to
lean body mass for parameters outlined in Table 1. We
will also perform a Dual-energy X-ray absorptiometry
(DXA) scan for body composition in South Africa and
use it to examine validity of the BIA measurements
across countries.
Laboratory investigations
The key laboratory measurement for this study will be
iohexol (Omnipaque 300 and 350 mg I/mL, GE Health-
care) clearance. The iohexol measured GFR will serve as
the gold standard for comparison with other methods.
Using aseptic technique study nurses will insert an IV
line into the non-dominant arm of the participant and
use the line for subsequent blood draws. We will admin-
ister a single dose of 5 ml of iohexol over 30 s through
an intravenous cannula inserted in the dominant arm
contralateral to the established IV line, followed by a 10
ml normal saline flush. We will weigh the iohexol dose
in grams to a specificity of 0.01 g by weighing the syringe
before and after administration of the iohexol. The re-
search nurses will draw four milliliters of blood for the
iohexol assay again at approximately 5, 120, 180 and
240 min after injection of iohexol, and record the exact
time. We will calculate the GFR using a single compart-
ment model based on iohexol clearance between 120
and 240 min.
In Uganda at the time points of 120 and 240 min, we
will also collect a capillary sample of dried blood spots
to compare to intravenous sampling of iohexol GFR as a
modification from previous studies [11, 30]. Should this
method prove to be accurate, it will greatly facilitate fur-
ther studies in resource-limited settings. In order to
avoid inter-laboratory variations, all plasma and blood
spot samples of iohexol will be measured at the National
Health Laboratory, Johannesburg, South Africa by ultra-
pressure liquid chromatography-tandem mass spectrom-
etry with identification and quantitation based on MRM
transitions. The laboratory is accredited for the Inter-
national Organization for Standardization (ISO) stand-
ard 15,189 and also participates in the internal quality
control run at a high and a low level every 20 samples.
The laboratory has participated in Equalis external con-
trol since 2017.
We will measure creatinine using the enzymatic method
in Uganda and Jaffe for South Africa and Malawi standard-
ized against an isotope dilution mass spectrometry (IDMS)
method across all sites. We will adopt the recommended
estimation and reporting format or measured renal func-
tion proposed by Fabian et al [31]. We will measure serum
cystatin C to determine the accuracy of the cystatin-based
CKD-EPI equations. We will measure Cystatin C using the
standardized Roche Gen2 assay, which has been standard-
ized against certified reference material (ERM-DA471/
IFCC). To minimise batch variation, samples will be
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analysed at the end of the study at one central laboratory at
MRC/UCRI&LSHTM for Uganda and Malawi while the
samples in South Africa will be analysed at the National
Health Laboratory, Johannesburg, South Africa. To under-
stand laboratory differences and enable calibration we will
cross-validate and measure 50-paired samples for creatinine
in Uganda, Malawi and South Africa, and cystatin between
South Africa and Uganda. Additional tests include full
blood count (including haemoglobin level), tests for screen-
ing of infections (malaria, streptococcal infections, Hepatitis
B, Hepatitis C and HIV Infection), C-reactive protein, ran-
dom blood glucose, HbA1c and the fasting lipid profile as
markers of metabolic risk.
We will perform four urine tests. We will take an early
morning spot urine sample for quantitative urine albu-
min: creatinine ratio, an early morning urine dipstick
analysis to qualitatively assess haematuria, leucocyturia
and proteinuria, and microscopy will be performed on
the centrifuged urine to screen for urinary schistosomia-
sis within 1–2 h of collection. We will take a 24-h urine
collection for urinary albumin excretion, sodium and 24-
h creatinine clearance in a sample of 300 participants
from Uganda during the second phase of the study.
Details of the equipment used for the measurements
are outlined in Table 1 below.
Qualitative sub-study in Uganda
The qualitative sub-study in Uganda will have two com-
ponents: a study of people with abnormal renal function,
and an enquiry into medicinal product supply and use
sourced from traditional healers and herbalists.
This sub-study of people with abnormal renal function
will include up to 50 participants found to have CKD
during the recruitment of the 1000 participants for the
overarching study. In order to recruit a comparator
group for the 50 CKD participants, a further 50 partici-
pants without CKD of a similar age living in a neighbor-
ing house to each case will be invited to take part. Data
from both cases and ‘controls’ will be collected through
two in-depth interviews. These selections were made on
an estimated sample to reach saturation.
For the sub-study with traditional healers/herbalists,
we will approach ten traditional healers and herbalists
and invite them to participate in one or more interviews
to discuss the common ailments they treat and the types
of herbal and other preparations that they use in their
practice.
Bio-banking
Serum, plasma and urine samples will be collected, proc-
essed and frozen and transported to the central labora-
tory for additional tests that cannot be conducted at the
originating laboratory. All three centers have quality as-
surance systems for processing, sample transportation
and sample storage management systems [26, 32, 33].
All sites have received ethical approval for testing of
specimens for genetic studies and exploration of new
markers of CKD.
Data management
Data management will follow local established proce-
dures ensuring quality, confidentiality and proper use of
abnormal results to guide patient care when needed.
Electronic data capture allows automatic data checks
such as double entry of numbers and range checks. We
will enter anonymized data into compatible statistical
databases from centres in all three countries to for shar-
ing between all investigators.
Quality assurance
All three centres have quality assurance procedures that
support the studies at different levels. Study staff are
trained and certified according to national and inter-
national guidelines governing research. The ARK team
holds regular meetings to ensure that study protocols
and research standards are adhered to. We will follow
standard sample storage protocols for the biorepository.
Statistical and qualitative analysis plan
We will tabulate baseline characteristics stratified by
country. We will perform initial analyses in a sample of
1500 participants selected to represent all centres, ages,
sex, and eGFR categories for modification of the equa-
tion, and allow for subsequent validation using the
remaining data. We plan to recombine the training and
test sets for fitting a final model. We are also open to al-
ternatives to data-splitting such as re-sampling tech-
niques (cross-validation and bootstrapping), that would
allow us to develop the model on the whole dataset and
still validate predictive accuracy. Evidence from previous
derivation of eGFR equations suggests that errors are
multiplicative, so we will do analysis on the log (ioxehol-
GFR) scale. To determine the measured GFR (iohexol-
GFR); we will calculate the slope from the 3 samples at
120, 180 and 240 min points using the exact time of col-
lection turn these into a GFR normalised to BSA using
standard methods [13, 34]. We will also put in the R-
value of the fit, which will be used to exclude ones
where the fit is particularly poor. In our primary analysis
we will evaluate the performance of the CockCroft
Gault, 4v-MDRD, CKD-EPIcr, CKD-EPIcyst, CKD-
EPIcr/cyst equations with and without ethnic correction
factor by calculating the bias, precision and accuracy at
10% (P10) and 30% (P30) compared to iohexol GFR as
done by previous studies [13]. Derivation of GFR esti-
mating equations is rapidly developing and we will also
consider evaluation against newly developed methods in-
cluding the full age spectrum (FAS) and the Lund-
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Malmo GFR estimating equations [35, 36]. We will as-
sess the performance of the different equations for
eGFRs with and without ethnic factors using Lin’s Con-
cordance Correlation Coefficient and Spearman correl-
ation coefficients to evaluate the degree to which pairs
of observations fall on the 45° line through the origin.
We will calculate bias and relative bias. We will evaluate
precision by the standard deviation of the bias (random
error) and root-mean-square error. We will test the dif-
ference in P30 accuracy between eGFRs with the exact
McNemar test.
We will use Bland-Altman plots to investigate the
measurement error of existing equations of log(MDRD-
eGFR), log(CKD-EPI-eGFR), log(CG-eGFR) and log(cys-
tatin C-eGFR) compared to log(ioxehol-GFR). If needed,
to develop modified correction factors for the setting, we
will carry out regressions to predict log(ioxehol-GFR) as
a function of age, gender, and creatinine/cystatin C. Pre-
dicted eGFRs will subsequently be compared with mea-
sured GFRs in the validation sample. We will investigate
what happens if information on weight, height, and
bioimpedance measures are added to the regression
model and use computed R2 values to investigate
whether anthropometry adds relevant information over
and above existing equations.
All statistical analyses will be performed using STATA
15 SE (Stata Corp, Texas, USA).
For the qualitative study, we will record interviews
with permission from the participant and transcribe and
translate them. We will revise the interview guidance
after the initial interviews in order to collect greater
depth of data on emerging themes. We will review tran-
scripts for accuracy and enter these into Dedoose, quali-
tative data analysis software. We will conduct data
analysis using an iterative coding process, during the
interview period. After data collection, we will perform
open coding, and move to more refined codes, sub-
themes, and then themes. We will analyze themes and
code them using a constant comparison method. We
will apply the codes to interview transcripts and sum-
mary statements with representative quotes developed
for each theme.
Ethical considerations
We have obtained ethical approvals from the Uganda
Virus Research Institute, Research Ethics Committee
(UVRI-REC-#HS 1978) the Uganda National Council for
Science and Technology (UNCST-#SS 4283), from the
Malawi National Health Sciences Research Committee
(#1072) and the University of Witwatersrand Human Re-
search Ethics Committee (#M160938).
We will obtain written informed consent from partici-
pants for the collection and analysis of genetic samples
as well as iohexol testing and for the use of their clinical
records for research purposes. We will seek approval for
all study procedures including material transfer agree-
ments from the respective ethical review boards. In case
we diagnose medical conditions through study screening,
we will refer the participants to appropriate medical fa-
cilities. We will refer participants found to have ad-
vanced CKD to appropriate nephrology services as
directed by the study physicians in each centre.
Discussion
This study aims to establish the optimal approach to es-
timate GFR in sub-Saharan Africa. Our study has the ad-
vantage of drawing participants from three countries
and both rural and urban settings within sub-Saharan
Africa, which will increase the applicability of the find-
ings across the region. Furthermore, we embedded the
ARK study within established cohorts that have back-
ground data and longitudinal serial measures that we
can use to characterize kidney disease over a period. The
study will seek to overcome a number of the limitations
of previous research.
There are challenges with measuring iohexol GFR,
with the major one being accuracy of measurement of
iohexol [23, 37]. Stringent measures, shared standard op-
erating procedures across the centres, and analysis in
one certified laboratory will help minimise errors.
Measurement of creatinine is another challenge. Cre-
atinine is influenced by many factors and these can
greatly influence the estimation, particularly at low eGFR
[19, 37, 38]. It is particularly important that the methods
used for creatinine measurements are the same across
sites and are validated across the centres. We opted to
use the Jaffe method for South Africa and Malawi and
enzymatic method in Uganda, standardized against an
isotope dilution mass spectrometry method across all
sites to improve the accuracy in measurement. We will
measure Cystatin C in order to assess whether the
addition of cystatin C by itself or in combination with
creatinine assays further refines the accuracy of estimat-
ing GFR within SSA. Several studies have shown that the
addition of cystatin C to the estimation formula im-
proves its accuracy [39, 40] and using CKD-EPI-
creatinine/cystatin C improved the accuracy in a study
from Congo [13]. Using a unified approach, these issues
will be addressed by this study. We also plan to measure
bioimpedance to define body composition and its contri-
bution to measured GFR variation across the sites, and
to assess the correlation of body composition measured
by BIA with the gold standard, DXA – which will be
done in South Africa [41]. Bioimpedance measurement
was included in this study for measurement of lean mass
and total body water and we hope to use it to optimize
GFR estimation on an individual patient basis, for ex-
ample in a patient with significant oedema. While this
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has not proven useful in high-income settings, such
technologies may be useful in low-resource settings [42].
Bio-impedance will help in incorporating more parame-
ters allowing more flexibility to work with the data to
get the best formula.
Assessment of risk factors for CKD in sub-Saharan Af-
rica has previously been hampered by inaccurate meas-
urement of GFR. Although, not exhaustive, we included
a number of risk factors for CKD in our study. We will
examine the role of traditional cardiovascular risk factors
including diabetes mellitus, obesity and lipid profiles
along with conventional and ambulatory blood pressure
monitoring. In addition we will measure the impact of
infections which may be of great importance in this re-
gion where infectious diseases are common and may
play a major role in disease causation alongside genetic
factors [43–49].
However, there are limitations. Prolonged blood sam-
pling for iohexol excretion may help to define GFR in
patients with very poor renal function [23]. We chose
not to include this in our protocol to minimize partici-
pant burden. In addition, we do not include participants
from other regions of sub-Saharan Africa, including
Central and West Africa but we welcome data-sharing
with studies in other regions.
The African Research into Kidney disease (ARK) col-
laboration will provide definitive information about opti-
mal measurement of renal function in sub-Saharan
Africa, and is an opportunity for establishing close work-
ing relationships across different centres, using standard-
ized protocols and measurements, and shared bio-
repositories. We plan to build on the collaboration for
this study and for future work on kidney disease in sub-
Saharan Africa, and welcome additional partners from
across the region including North African and Arab
populations.
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